DETAILS ON THE HIPEC PROCEDURE. PAM PHILLIPS IS GRATEFUL FOR EVERY MINUTE IN 2020 FOR 11 NEWS FIRST CAUGHT UP WITH HER NINE YEARS AGO WHEN SHE WAS A NEW CANCER SURVIVOR IN 2009, SHE WAS DIAGNOSED WITH ...

HIPEC addition to SCS did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer patients. Both SCS alone and SCS with HIPEC groups exhibited similar safety profiles, ...

Patients with advanced ovarian cancer undergoing interval cytoreductive surgery who received paclitaxel-based hyperthermic intraperitoneal chemotherapy (HIPEC) during surgery appeared to have ...

Adding hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery significantly improved overall survival (OS) in women with platinum-sensitive, recurrent epithelial ovarian carcinoma, ...

Adding hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C to surgery for locally advanced colorectal cancer (CRC) significantly reduced the risk of locoregional recurrence, the ...

A technique that delivers high doses of heated chemotherapy directly to the abdominal cavity is a promising treatment for certain patients with Stage IV cancer. Hyperthermic intraperitoneal ...

SCS combined with HIPEC may improve overall survival in PSROC patients compared to SCS alone, with a statistically significant benefit observed. The risk of severe complications, including anemia and ...

LUBBOCK, Texas (KCBD) - When we think of cancer, we think of cancer tied to an organ like lung cancer. But abdominal cancer can include so much more than the organs inside the belly. The good news is ...

Credit: Getty Images. Adding HIPEC to interval cytoreductive surgery improves long-term outcomes in stage III epithelial ovarian cancer, a phase 3 trial suggests. Adding hyperthermic intraperitoneal ...

SEATTLE — Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) is a complex treatment where chemotherapy is delivered into the abdomen through catheters after the extensive surgical removal of a tumor ...

A randomized, multicenter, open-label phase III trial of hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer (KOV-HIPEC-02). This is an ASCO Meeting Abstract from ...